GUANGZHOU, China, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) (the “Company” or “Burning Rock”), a…
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly…
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM,…
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, October 2nd at 4:00 PM ETOCALA,…
Phase 3 ENLIGHTED study enrollment completion expected by first quarter of 2025TEL AVIV, Israel, Sept. 27, 2024 (GLOBE NEWSWIRE) --…
– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor…
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 – – Retiring $17.5…
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark…
New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute…
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for…